HSTM Earnings Day: Shorts Steady, Borrow Loose

HealthStream reports this morning with positioning that has largely been documented heading into the print — two prior articles captured the short-interest build and the defensive options pivot — but the final data points add nuance worth noting.

The short-selling picture has stabilised at an elevated level. Shares short ended July at 1.13 million, representing 3.8% of the free float — up 12.6% on the week and 15.2% over the past month, the highest level in the visible history. That build, concentrated in the July 22–24 window, has not unwound. Yet the borrow market itself tells a relaxed story. Availability remains extraordinarily loose at 3,399% — meaning shares available to borrow dwarf those actually borrowed by a factor of roughly 34 to 1. Borrowing costs have also fallen sharply, down 56% over the past month to just 0.51% annually. Short sellers built their positions at no real friction, and there is no squeeze dynamic in the lending pool to force a rapid unwind.

Options positioning remains more defensive than HSTM's recent history, though it has eased from its peak. The put/call ratio holds at 0.77 — roughly double the 20-day mean of 0.36 — running about 1.25 standard deviations above average. That compares to the 2.1 z-score flagged earlier in the week, so the hedging intensity has moderated. For context, calls dominated HSTM's options activity throughout most of 2026; the sustained shift toward puts represents a genuine change in character, even if it has cooled. Canaccord Genuity — the lone active analyst voice — raised its target to $27 on July 21 while maintaining a Hold rating, leaving the stock trading above that level at $28.33. The consensus mean target of $33.50 implies roughly 18% upside, though the analyst picture is sparse enough that the mean carries limited informational weight.

The two prior earnings events on record produced modest and conflicting reactions: a 3% gain and then a 2.2% decline over the subsequent five trading days in each case. Neither was dramatic. The print is therefore less about a binary directional call and more about whether management can demonstrate that the healthcare workforce platform continues to grow at a pace that justifies the stock's current 49x trailing earnings multiple — a question the short build and defensive options positioning suggest at least some participants are unwilling to take on faith.